Hydrochlorothiazide; metoprolol succinate - Generic Drug Details
What are the generic drug sources for hydrochlorothiazide; metoprolol succinate and what is the scope of patent protection?
Hydrochlorothiazide; metoprolol succinate
is the generic ingredient in one branded drug marketed by Concordia and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for hydrochlorothiazide; metoprolol succinate
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | hydrochlorothiazide; metoprolol succinate at DailyMed |
Recent Clinical Trials for hydrochlorothiazide; metoprolol succinate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AstraZeneca | Phase 3 |
See all hydrochlorothiazide; metoprolol succinate clinical trials
Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; metoprolol succinate
US Patents and Regulatory Information for hydrochlorothiazide; metoprolol succinate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordia | DUTOPROL | hydrochlorothiazide; metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 021956-003 | Aug 28, 2006 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Concordia | DUTOPROL | hydrochlorothiazide; metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 021956-002 | Aug 28, 2006 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Concordia | DUTOPROL | hydrochlorothiazide; metoprolol succinate | TABLET, EXTENDED RELEASE;ORAL | 021956-001 | Aug 28, 2006 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Hydrochlorothiazide and Metoprolol Succinate Market Dynamics, Patent Position, and Financial Trajectory
Hydrochlorothiazide and metoprolol succinate represent a mature antihypertensive combination with limited current brand value and substantial generic pricing pressure. The fixed-dose product historically associated with the combination was Dutoprol, an extended-release metoprolol succinate and hydrochlorothiazide product marketed by AstraZeneca. The active ingredients remain widely used, but the commercial opportunity is concentrated in low-cost generic supply, hospital formularies, and combination-pill adherence strategies rather than premium branded sales.
What is the commercial product containing hydrochlorothiazide and metoprolol succinate?
The combination pairs:
- Hydrochlorothiazide, a thiazide diuretic.
- Metoprolol succinate, an extended-release beta-1 selective blocker.
Metoprolol succinate is the extended-release formulation of metoprolol. It differs from metoprolol tartrate, which is an immediate-release formulation. This distinction matters because older combination products, including Lopressor HCT, used metoprolol tartrate rather than metoprolol succinate.
Dutoprol was approved for hypertension in patients requiring both a beta blocker and a diuretic. The product was supplied in fixed-dose strengths combining extended-release metoprolol succinate with hydrochlorothiazide. The FDA labeling stated that the product was not intended as initial therapy and that dose selection should account for the individual dose requirements of both components (U.S. Food and Drug Administration, n.d.-a).
The combination has limited current commercial visibility. Metoprolol succinate extended-release is primarily sold as a standalone generic equivalent to Toprol-XL. Hydrochlorothiazide is available as a low-cost standalone generic and in multiple fixed-dose combinations, including products with lisinopril, losartan, valsartan, and other antihypertensive agents.
How large is the market for hydrochlorothiazide and metoprolol succinate?
The addressable market is a mature generic hypertension segment rather than a high-growth specialty market.
| Market characteristic | Assessment |
|---|---|
| Therapeutic area | Hypertension and cardiovascular risk reduction |
| Primary dosage form | Oral tablets |
| Brand reference product | Historically Dutoprol |
| Main active-ingredient brands | Toprol-XL for metoprolol succinate; Microzide and others for hydrochlorothiazide |
| Current pricing model | Generic, formulary-driven |
| Prescription growth | Low to moderate, linked to hypertension prevalence |
| Unit-price trend | Long-term decline after generic entry |
| Brand differentiation | Limited |
| Manufacturing complexity | Low to moderate |
| Regulatory pathway | ANDA for generic products; NDA or 505(b)(2) for differentiated products |
| Commercial risk | Price erosion, fragmented suppliers, limited switching incentives |
Hypertension creates a large underlying patient population. The American College of Cardiology and American Heart Association guidelines generally prioritize thiazide-type diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers for initial treatment, while beta blockers are used selectively, including in patients with ischemic heart disease, arrhythmias, or other cardiovascular indications (Whelton et al., 2018).
That treatment positioning limits the growth potential of a metoprolol-hydrochlorothiazide combination. The product is most relevant for patients already receiving both agents or for prescribers seeking to reduce pill burden. It is less attractive as a broad first-line hypertension product.
When did hydrochlorothiazide and metoprolol succinate lose exclusivity?
The key commercial exclusivity events occurred years ago.
| Asset | Commercial role | Exclusivity status |
|---|---|---|
| Dutoprol | Fixed-dose metoprolol succinate/hydrochlorothiazide | Historical brand product; no meaningful current exclusivity premium |
| Toprol-XL | Extended-release metoprolol succinate | Core patent and regulatory exclusivity have expired |
| Hydrochlorothiazide | Generic diuretic component | Long off-patent |
| Combination product | Fixed-dose tablet | Subject to generic substitution and formulation-specific approval requirements |
The principal market protection for metoprolol succinate extended release expired after the original Toprol-XL patent and regulatory exclusivity period. Hydrochlorothiazide has been generic for decades. Any current protection would therefore depend on product-specific formulation, manufacturing, or method-of-use patents rather than basic composition-of-matter rights.
The product’s economics are consequently determined by generic approval status, supply reliability, channel access, and reimbursement contracts.
What patents protect metoprolol succinate and hydrochlorothiazide products?
The basic active ingredients are not protected by enforceable composition-of-matter patents in the United States. Relevant patent categories are narrower:
Extended-release metoprolol formulations
Patent activity historically focused on:
- Controlled-release tablet architecture.
- Release-rate characteristics.
- Succinate salt formulation.
- Matrix or polymer systems.
- Manufacturing processes.
The commercial importance of these patents declined after generic extended-release metoprolol succinate products entered the market. Generic manufacturers were able to obtain approval through ANDA pathways once applicable barriers expired or were successfully challenged.
Fixed-dose combination formulations
A fixed-dose combination can raise separate formulation issues, including:
- Compatibility between hydrochlorothiazide and metoprolol succinate.
- Extended-release performance.
- Dose proportionality.
- Tablet compression and stability.
- Dissolution specifications.
- Manufacturing process controls.
These issues can support formulation patents, but they generally provide narrower protection than a new chemical entity patent. A formulation patent must also withstand obviousness, written-description, enablement, and infringement challenges.
Method-of-use patents
Method-of-use protection is limited for a conventional antihypertensive combination. Potential claims could address:
- Treatment of hypertension in defined patient populations.
- Reduction of cardiovascular events.
- Use in patients requiring both beta blockade and diuresis.
- Dosing schedules or titration protocols.
Method-of-use patents are commercially weaker when the same active ingredients are already prescribed separately for the same disease. Generic manufacturers may use “skinny label” strategies to omit patented indications where permitted by FDA and patent law.
What is the Orange Book status of the combination?
FDA Orange Book status is product-specific. The relevant reference product is the fixed-dose metoprolol succinate/hydrochlorothiazide product rather than either active ingredient considered separately.
For mature or discontinued products, several points affect interpretation:
- A discontinued product may remain listed in FDA databases.
- Listing does not establish that the product is currently marketed.
- A product can be discontinued for commercial reasons without a safety or efficacy withdrawal.
- Patent listings can expire while the reference product remains in the database.
- Generic approval may not occur if market demand is too small to justify development.
The Orange Book should therefore be read together with FDA product-status records and current commercial availability. A historical listing does not create a current branded revenue stream (U.S. Food and Drug Administration, n.d.-b).
Are there Paragraph IV challenges or patent litigation risks?
The current Paragraph IV risk is likely low relative to newer branded medicines because the relevant composition and core formulation rights are mature or expired.
The principal litigation scenarios would involve:
- A new extended-release fixed-dose formulation.
- A manufacturer seeking approval before expiration of a listed formulation patent.
- Disputes over bioequivalence or dissolution testing.
- Allegations involving process patents.
- A later entrant pursuing an authorized-generic or 505(b)(2) strategy.
For an established generic product, litigation risk is more likely to involve ordinary ANDA patent certification issues than high-value market exclusivity disputes. The economic value of litigation is constrained by low expected net prices and the availability of substitute antihypertensive products.
No major current litigation materially changes the commercial outlook for the conventional hydrochlorothiazide/metoprolol succinate combination based on the mature status of the product class.
What is the FDA regulatory status?
The active ingredients have extensive FDA experience:
- Hydrochlorothiazide is approved in numerous generic antihypertensive products.
- Metoprolol succinate extended release is approved as a standalone product and in generic equivalents to Toprol-XL.
- Fixed-dose combinations require product-specific demonstration of pharmaceutical quality, bioequivalence, and appropriate labeling.
- An applicant cannot automatically rely on approval of the separate components to market a combined extended-release product.
A new entrant could use an ANDA if an appropriate reference product and pathway are available. A reformulated or clinically differentiated product might require an NDA or 505(b)(2) application. The regulatory burden is higher for a novel release mechanism, a new strength, or a product with a materially different indication.
How strong is the patent estate?
The patent estate is weak for the basic drug combination and moderate only for technically differentiated delivery systems.
| Patent category | Current strength |
|---|---|
| Hydrochlorothiazide composition | Very weak or expired |
| Metoprolol succinate composition | Expired or commercially exhausted |
| Conventional immediate-release combination | Weak |
| Extended-release formulation | Historically meaningful, now largely exhausted |
| Novel controlled-release technology | Potentially moderate |
| Manufacturing process | Narrow and difficult to monetize |
| Method of use | Limited by established generic uses |
| Brand trademark | Minimal value without active promotion and distribution |
A new product would need to create value through adherence, dosing convenience, pharmacokinetic differentiation, or channel economics. Patent protection alone would not support a large premium unless the product demonstrated a clinically meaningful advantage.
What are the main market dynamics?
Generic price erosion
The principal force is price competition. Once multiple ANDA holders enter, reimbursement contracts and pharmacy purchasing organizations tend to push prices downward. Metoprolol succinate extended-release tablets are available from multiple suppliers, reducing the bargaining power of any single manufacturer.
Low switching costs
Patients and prescribers can use the two agents separately. This limits dependence on a single fixed-dose product. A patient can receive metoprolol succinate extended release plus hydrochlorothiazide as separate tablets with little clinical disruption.
Pill-burden reduction
The combination has a practical adherence benefit. A single tablet can reduce the number of daily pills, although the benefit is offset when clinicians need to adjust the beta blocker and diuretic independently.
Guideline positioning
Beta blockers are not preferred as universal first-line therapy for uncomplicated hypertension. This constrains volume growth. The strongest demand comes from patients with coexisting coronary artery disease, tachyarrhythmia, prior myocardial infarction, or other reasons to use beta blockade.
Supply-chain economics
Manufacturing is less complex than for sterile injectables or biologics, but extended-release products require reliable control of dissolution and content uniformity. Supplier concentration or manufacturing deviations can create temporary shortages even in an off-patent market.
What financial trajectory should investors expect?
The financial trajectory is best described as mature, low-margin, and volume-stable.
| Period | Expected financial pattern |
|---|---|
| Brand launch period | Limited premium pricing supported by product convenience |
| Generic-entry period | Rapid unit-price decline and share fragmentation |
| Mature generic period | Stable demand with low gross margins |
| Current outlook | Modest volume opportunity, limited revenue expansion |
| Upside case | Supply shortage, contract win, or differentiated adherence product |
| Downside case | Additional entrants, reimbursement cuts, manufacturing exit |
There is no reliable basis for attributing material current revenue to the fixed-dose combination itself. Historical brand sales, if reported, would have been embedded within broader cardiovascular portfolios and would not necessarily be disclosed as a standalone line item.
For a generic manufacturer, the opportunity depends on:
- Approval timing.
- Number of competing suppliers.
- Wholesale acquisition cost.
- Medicaid and Medicare reimbursement.
- Manufacturing yield.
- Contract manufacturing cost.
- Ability to maintain uninterrupted supply.
For an innovator, the combination is unlikely to support meaningful premium revenue without a new delivery platform or clinical positioning. For a generic company, it may be a portfolio-completion product that improves formulary coverage but contributes limited standalone earnings.
How does this combination compare with competing antihypertensive products?
| Product class | Generic competition | Guideline position | Commercial outlook |
|---|---|---|---|
| Metoprolol succinate alone | High | Selective use | Large, mature generic market |
| Hydrochlorothiazide alone | High | Established diuretic option | Very low-cost market |
| Metoprolol plus hydrochlorothiazide | Moderate to high | Selected patients | Limited fixed-dose opportunity |
| ACE inhibitor plus hydrochlorothiazide | High | Common combination strategy | Larger combination market |
| ARB plus hydrochlorothiazide | High | Common combination strategy | Stronger commercial relevance |
| Calcium-channel blocker combinations | High | Common first-line use | Broad generic demand |
ACE inhibitor/hydrochlorothiazide and ARB/hydrochlorothiazide combinations generally have stronger positioning in routine hypertension than beta blocker/diuretic combinations. That difference reduces the addressable market for metoprolol succinate/hydrochlorothiazide.
What generic launch scenarios exist?
A potential generic entrant would face three scenarios:
- Direct ANDA competition against an available reference product, producing rapid price erosion.
- Entry into a limited-demand niche where few manufacturers participate but volumes remain small.
- Reformulation through an NDA or 505(b)(2) pathway, with higher development costs and uncertain reimbursement support.
The most attractive generic scenario would involve limited competition combined with a reliable supply position. The least attractive scenario would involve multiple approved suppliers and no meaningful differentiation from separate-component therapy.
Key Takeaways
- Hydrochlorothiazide and metoprolol succinate are mature, off-patent antihypertensive ingredients.
- Dutoprol was the principal historical fixed-dose product associated with the combination.
- The commercial market is dominated by generic pricing and formulary economics.
- Core composition patents have no meaningful remaining value.
- Formulation and manufacturing patents could protect a differentiated product but would be narrow.
- The combination has weaker first-line guideline positioning than ACE inhibitor, ARB, and calcium-channel blocker combinations.
- Financial upside is limited unless tied to supply scarcity, a contract win, or a clinically differentiated extended-release platform.
- Generic entry risk is high in principle, but the market may be too small to attract numerous dedicated entrants.
- Current value is more likely to reside in reliable manufacturing and portfolio efficiency than in brand pricing power.
FAQs
Is hydrochlorothiazide with metoprolol succinate still widely prescribed?
The individual ingredients remain widely prescribed, but the fixed-dose combination has substantially less commercial visibility than standalone metoprolol succinate or other hydrochlorothiazide combinations.
Is Dutoprol still a major branded product?
No. Dutoprol has historical significance as the fixed-dose combination, but it does not have the commercial profile of an actively promoted, high-growth cardiovascular brand.
Can a generic manufacturer combine metoprolol succinate and hydrochlorothiazide?
Yes, but the manufacturer must satisfy the applicable FDA approval pathway, including formulation, stability, dissolution, and bioequivalence requirements for the specific product.
Does metoprolol succinate have stronger patent protection than hydrochlorothiazide?
Historically, yes. Extended-release metoprolol succinate required more complex formulation protection. Hydrochlorothiazide has been generic for substantially longer. Neither ingredient has meaningful new-molecule exclusivity today.
Would a single-tablet combination command a price premium?
Usually not in the mature generic market. A premium would require demonstrated adherence benefits, a differentiated release profile, limited competition, or favorable payer contracting.
References
-
American College of Cardiology/American Heart Association. (2017). Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
-
U.S. Food and Drug Administration. (n.d.-a). Dutoprol prescribing information: Metoprolol succinate and hydrochlorothiazide extended-release tablets.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs database.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
More… ↓
